Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.84 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | GLA | P06280 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130707 | 1.00 | TOP1 (0.84) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL30902657 | 1.00 | TOP1 (0.84) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL29363060 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL1005149 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL19236135 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL29649464 | 0.94 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL27606708 | 0.93 | TOP1 (0.86) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL11070279 | 0.93 | TOP1 (0.86) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL27426962 | 0.93 | TOP1 (0.84) | TOP1MEN1KMT2AALDH1A1GLA | |
| Ammonia Solution, Strong SCHEMBL28299902 | 0.93 | TOP1 (0.84) | TOP1MEN1KMT2AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101904-A1 | NOREPINEPHRINE TRANSPORTER-TARGETED PRODRUGS FOR CANCER THERAPY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2024080726-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING NATURAL KILLER CELLS AND TOPOISOMERASE INHIBITOR AS ACTIVE INGREDIENTS | (주) 테라베스트 | 2024-04-18 | — | — | WO | claimed |
| CN-110200920-B | Reduction-sensitive pharmaceutical composition and preparation and application thereof | 东南大学 | 2022-03-08 | — | — | CN | claimed |
| CN-110302159-B | Reduction sensitive lipid pharmaceutical composition and preparation method and application thereof | 东南大学 | 2021-12-24 | — | — | CN | claimed |
| EP-1003516-A4 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | UNIV GEORGE WASHINGTON (US) | 2006-07-12 | — | — | EP | claimed |
| US-6635628-B2 | Administering camptothecin compounds at an alkaline pH for inhibiting diarrhea side effect of camptothecin compounds | THE GEORGE WASHINGTON UNIVERSITY | 2003-10-21 | — | — | US | claimed |
| US-20020193391-A1 | Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects | BOUSCAREL BERNARD (US) | 2002-12-19 | — | — | US | claimed |
| US-6407117-B1 | ADMINISTERING IRINOTECAN HYDROCHLORIDE AND BICARBONATE TO MAINTAIN INTESTINAL LUMEN ALKALINITY AND PREVENT DIARRHEA; AIDS TREATMENT | THE GEORGE WASHINGTON UNIVERSITY | 2002-06-18 | — | — | US | claimed |
| EP-1003516-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | The George Washington University (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999065493-A9 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | UNIV GEORGE WASHINGTON (US) | 2000-03-23 | — | — | WO | claimed |
| WO-1999065493-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-12-23 | — | — | WO | claimed |
| US-RE32518-E | Camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1987-10-13 | — | — | US | claimed |
| EP-0056692-B1 | 7-SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-08-14 | — | — | EP | claimed |
| US-4399282-A | 7-HYDROXYALKYL DERIVATIVES USING FREE RADICAL CATALYSTS; ANTITUMOR AND -CARCINOGENIC AGENTS; NONTOXIC | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1983-08-16 | — | — | US | claimed |
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | claimed |
| JP-57116076-A | — | — | None | — | — | JP | disclosed |
| JP-56012393-A | — | — | None | — | — | JP | disclosed |
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | disclosed |
| JP-S57116076-A | NOVEL CAMPTOTHECIN DERIVATIVE AND ITS PREPARATION | YAKULT HONSHA CO LTD | 1982-07-19 | — | — | JP | disclosed |
| JP-S5612393-A | NOVEL CAMPTOTHECIN DERIVATIVE | YAKULT HONSHA CO LTD | 1981-02-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193391-A1 | Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects | SI, SLC10A2, TOP2A | TOP1 4/4885MEN1 1206/4885KMT2A 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.